induction tumour immunity targeted inhibition nonsense-mediated mrna decay
main reason tumours controlled immune system unlike pathogens express potent tumour rejection antigens tras tumour vaccination aims stimulating systemic immune response targeted mostly weak antigens expressed disseminated tumour lesions main challenges developing effective vaccination protocols identification potent broadly expressed tras- effective adjuvants stimulate robust durable immune response- describe alternative approach expression new thereby potent antigens induced tumour cells inhibiting nonsense-mediated messenger rna decay nmd- small interfering rna sirna-mediated inhibition nmd tumour cells led expression new antigenic determinants immune-mediated rejection subcutaneous metastatic tumour models tumour-targeted delivery nmd factor-specific sirnas conjugated oligonucleotide aptamer ligands led significant inhibition tumour growth superior vaccination granulocyte-macrophage colony-stimulating factor gm-csf-expressing irradiated tumour cells enhanced co-stimulation tumour-targeted nmd inhibition forms basis simple broadly useful clinically feasible approach enhance antigenicity disseminated tumours leading immune recognition rejection cell-free chemically synthesized oligonucleotide backbone aptamer-sirnas reduces risk immunogenicity enhances feasibility generating reagents suitable clinical use
